<DOC>
	<DOC>NCT00655369</DOC>
	<brief_summary>In a Phase II trial in subjects with nonrestorative sleep, PD 0200390 demonstrated a positive treatment effect relative to placebo on the primary endpoint, the weekly version of the Restorative Sleep Questionnaire (RSQ-W). In this study, the dose-response relationship of varying doses of PD 0200390 using the Restorative Sleep Questionnaire (RSQ-W), will be explored in Nonrestorative Sleep subjects.</brief_summary>
	<brief_title>A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep</brief_title>
	<detailed_description />
	<criteria>Awake unrestored or unrefreshed, associated with significant distress or impairment in social, occupational, or other important areas of functioning during the daytime, for at least 3 nights for the past 3 months prior to screening Selfreport wake after sleep onset &lt;45 mins for past 3 mos; selfreport latency to sleep onset &lt;20 mins for past 3 mos PSG (Polysomnography) sleep criteria of wake after sleep onset &lt; 45 mins; Latency to persistent sleep &lt;20 mins. MAP (Multivariable Apnea Risk index) index &gt; or = 0.5 at screening BMI = or &gt; 32 kg/m2 History or presence of breathing related disorders PSG findings consistent with and periodic limb movement disorder, narcolepsy or other dyssomnia or parasomnia including apneahypopnea index &gt; 10/hr; or period limb movement with arousal index &gt; 10/hr.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>